Evolve Private Wealth LLC Purchases Shares of 1,259 Regeneron Pharmaceuticals, Inc. $REGN

Evolve Private Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,259 shares of the biopharmaceutical company's stock, valued at approximately $785,000.

Several other hedge funds have also recently made changes to their positions in the business. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth approximately $26,000. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $29,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Birchwood Financial Partners Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $32,000. 83.31% of the stock is owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock worth $1,090,030 in the last 90 days. Insiders own 6.97% of the company's stock.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Truist Financial increased their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an "equal weight" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an "overweight" rating on the stock in a report on Monday, May 18th. HSBC reduced their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a research report on Monday, July 6th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Sixteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $801.70.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $828.50 on Tuesday. The firm has a 50-day moving average of $701.36 and a 200-day moving average of $716.94. The company has a market cap of $85.30 billion, a P/E ratio of 20.48, a P/E/G ratio of 1.42 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $847.00.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the previous year, the company earned $12.81 earnings per share. The firm's revenue for the quarter was up 16.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source